SCHEMBL183773

SCHEMBL183773

CC(C)CNCc1cc(Cl)cc(CNCC(C)C)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.48
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 1/20 0.38
ESR1 P03372 1/20 0.37
CA2 P00918 6/20 0.36
GAA P10253 1/20 0.36
OPRL1 P41146 1/20 0.35
CHRM2 P08172 1/20 0.35
OPRM1 P35372 1/20 0.34
OPRK1 P41145 1/20 0.34
MAP4K4 O95819 1/20 0.34
MARS1 P56192 1/20 0.33
PNMT P11086 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27832335 0.87 POLB (0.43) POLBMEN1KMT2AALDH1A1HTT
SCHEMBL15771123 0.81 LMNA (0.59) MEN1KMT2AALDH1A1HTTSMN1; SMN2
SCHEMBL6566603 0.79 GAA (0.56) MEN1KMT2AALDH1A1SMN1; SMN2GAA
SCHEMBL183970 0.78 HDAC1 (0.36) POLBMEN1KMT2AALDH1A1HTT
SCHEMBL15859356 0.77 CA2 (0.49) MEN1KMT2AALDH1A1HTTSMN1; SMN2
SCHEMBL172648 0.77 POLB (0.42) POLBMEN1KMT2AALDH1A1HTT
SCHEMBL13041031 0.75 MAP4K4 (0.48) POLBMEN1KMT2AALDH1A1HTT
SCHEMBL1566716 0.75 POLB (0.56) POLBMEN1KMT2AALDH1A1HTT
SCHEMBL2769396 0.75 POLB (0.38) POLBMEN1KMT2AALDH1A1HTT
SCHEMBL19301034 0.73 PNMT (0.38) POLBMEN1KMT2AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501992-B2 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
US-8501992-B2 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
EP-2297103-B1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-01-04 EP disclosed
EP-2297103-B1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-01-04 EP disclosed
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US disclosed
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US disclosed
CN-102112445-A Hydroxyphenylsulfonamides as antiapoptotic Bcl inhibitors BRISTOL MYERS SQUIBB CO 2011-06-29 CN disclosed
WO-2009152082-A1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-17 WO disclosed
WO-2009152082-A1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BCL2, BAX, BCL2A1 POLB 2706/4885MEN1 4410/4885KMT2A 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.